Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NAPDH oxidase and NF kappa B activation

European Journal of Pharmacology

Volumn 629, Issue 1-3, 2010, Pages 153-158

  Liu, Xueping ^a   Luo, Dingzhen ^a   Zheng, Min ^a   Hao, Yuewei ^a   Hou, Liang ^a   Zhang, Suming ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Advanced glycation end product; Insulin resistance; NAPDH oxidase; Nuclear factor kappa B; Pioglitazone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; FRUCTOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PIOGLITAZONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; ESCAPE BEHAVIOR; FLUID INTAKE; INSULIN RESISTANCE; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BRAIN; DRINKING; FRUCTOSE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN RESISTANCE; MALE; MEMORY DISORDERS; NADPH OXIDASE; NF-KAPPA B; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; THIAZOLIDINEDIONES;

EID: 74149088832     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.059     Document Type: Article

References (37)

1. Bann H.F., and Higgins P.J. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213 (1981) 222-224
2. Bastaa G., Schmidtb A.M., and Caterina R.D. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Cardiovasc. Res. 63 (2004) 582-592
3. Blumberg B., and Evans R.M. Orphan nuclear receptors-new ligands and new possibilities. Gene. Dev. 12 (1998) 3149-3155
4. Brownlee M., Cerami A., and Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318 (1988) 1315-1321
5. Bucula R., and Cerami A. Advanced glycosylation: chemical, biology, and implications for diabetes and aging. Adv. Pharmacol. 23 (1992) 1-34
6. Castellani R.J., Harris P.L., Sayre L.M., Fujii J., Taniguchi N., Vitek M.P., Founds H., Atwood C.S., Perry G., and Smith M.A. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 15 31 (2001) 175-180
7. Culman J., Zhao Y., Gohlke P., and Herdegen T. PPAR-γ: therapeutic target for ischemic stroke. Trends. Pharmacol. Sci. 28 (2007) 244-249
8. Desouza C.V., Gerety M., and Hamel F.G. Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. Vasc. Pharmacol. 46 (2007) 188-194
9. Duan S.Z., Usher M.G., and Mortensen R.M. PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens. 18 (2009) 128-133
10. Fan Q., Liao J., Kobayashi M., Yamashita M., Gu L., Gohda T., Suzuki Y., Wang L.N., Horikoshi S., and Tomino Y. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol. Dial. Transplant. 19 (2004) 3012-3020
11. Gaikwad A.B., Viswanad B., and Ramarao P. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacol. Res. 55 (2007) 400-407
12. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke1 A., Dewachter I., Kuiperi C., O'Banion K., Klockgether1 T., Leuven F.V., and Landreth G.E. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
13. Iwai H., Ohno Y., and Aoki N. The effect of leptin, tumor necrosis factor-alpha (TNF-alpha), and nitric oxide (NO) production on insulin resistance in Otsuka Long-Evans fatty rats. Endocr. J. 50 (2003) 673-680
14. Klotz L., Schmidt M., Giese T., Sastre M., Knolle P., Klockgether T., and Heneka1 M.T. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor γ levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 175 (2005) 4948-4955
15. Ko L.W., Ko E.C., Nacharaju P., Liu W.K., Chang E., Kenessey A., and Yen S.H. An immunochemical study on tau glycation in paired helical filaments. Brain Res. 830 (1999) 301-313
16. Kuhad A., Bishnoi M., Tiwari V., and Chopra K. Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol. Biochem. Behav. 92 (2009) 251-259
17. Kumar P., and Kumar A. Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid-induced behavioral alterations and oxidative stress in rats. Pharmacol. Rep. 60 (2008) 706-715
18. McTigue D.M., Tripathi R., Wei P., and Lash A.T. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp. Neurol. 205 (2007) 396-406
19. Miles W.R., and Root H.F. Psychologic tests applied to diabetic patients. Arch. Intern. Med. 30 (1922) 767-777
20. Monnier V.M., Kohn R.R., and Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus (nonenzymatic glycosylation/ crosslinking/diabetes sequelae). Proc. Natl. Acad. Sci. U. S. A 81 (1984) 583-587
21. Moreno S., Farioli-Vecchioli S., and Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 12 (2004) 131-145
22. Ramasamy R., Vannucci S.J., Yan S.S.D., Herold K., Yan S.F., and Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15 (2005) 16R-28R
23. Singh R., Barden A., Mori T., and Beilin L. Advanced glycation end-products: a review. Diabetologia 44 (2001) 129-146
24. Stewart R., and Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet. Med. 16 (1999) 93-112
25. Storer P.D., Xu J., Chavis J., and Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161 (2005) 113-122
26. Suzuki M., Nomura C., Odaka H., and Ikeda H. Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. Jpn. J. Pharmacol. 74 (1997) 297-302
27. Wang K., Zhou Z., Zhang M., Fan L., Forudi F., Zhou X., Qu W., Lincoff A.M., Schmidt A.M., Topol E.J., and Penn M.S. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J. Pharmacol. Exp. Ther. 317 (2006) 37-43
28. Wahner A.D., Bronstein J.M., Bordelon Y.M., and Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69 (2007) 1836-1842
29. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., and Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950-958
30. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., and Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E685-E694
31. Wendt T., Tanji N., and Guo J. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 14 (2003) 1383-1395
32. Yamagishi S., Ueda S., Matsui T., Nakamura K., and Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr. Pharm. Des. 14 (2008) 962-968
33. Yamamoto Y., Maeshima Y., Kitayama H., Kitamura S., Takazawa Y., Sugiyama H., Yamasaki Y., and Makino H. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53 (2004) 1831-1840
34. Yeh C.H., Sturgis L., Haidacher J., Zhang X.N., Sherwood S.J., Bjercke R.J., Juhasz O., Crow M.T., Tilton R.G., and Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50 (2001) 1495-1504
35. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., and Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49 (2006) 3094-3099
36. Zhang X., Dong F., Ren J., Driscoll M.J., and Culver B. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp. Neurol. 191 (2005) 318-325
37. Zhao Z., Ho L., Wang J., Qin W., Festa E.D., Mobbs C., Hof P., Rocher A., Masur S., Haroutunian V., and Pasinetti G.M. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology. FASEB J. 19 (2005) 2081-2082